Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 4

Immune Spatial Features of Guselkumab Cutaneous Response

University of California, San Francisco · with Janssen Scientific Affairs, LLC · NCT05858632

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 4
Target enrollment
10
US sites recruiting
1
Study start
July 1, 2023
Record last updated
June 4, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.

Being studied: Guselkumab

Conditions: Psoriasis of Scalp

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria: possess a PSSI (psoriasis scalp severity index) of ≥12

Exclusion Criteria

  • taking systemic immunosuppressives in the last 4 weeks
  • pregnancy
  • severe immunodeficiency (either from genetic or infectious causes).
  • tuberculosis or other active serious infection
  • active systemic malignancy.
  • breast-feeding
  • Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
  • Males who are trying to conceive

-

Recruiting US locations

  • University of California San Francisco

    San Francisco, CA 94115

    Site contact: Jeffrey Cheng, MD, PhD · 415-575-0524 · rashes@ucsf.edu

Study contacts (from the official record)

  • Jeffrey Cheng, MD, PhD · 415 575 0524 · rashes@ucsf.edu
  • Raymond Cho, MD,PhD
All dermatology studies in California →
Immune Spatial Features of Guselkumab Cutaneous Response (NCT05858632) | Bored Studies